Clinical Trial:

A Phase 1 Study to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of EDO-S101, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

EDO-S101 has not been evaluated in any previous clinical studies and is not marketed anywhere. However, EDO-S101 was shown to be active in a number of relapsed/refractory hematologic malignancies both in laboratory test and in animal models.

 

This is the first study of EDO-S101 in humans. The main goal of this study is to assess the safety and tolerability of EDO-S101, a new anticancer drug that combines two known modes of action in one molecule. The concept is that these two mechanisms of action are complementary and might lead to substantial efficacy against the cancer.

 

This study will also determine the highest tolerable dose that can be given and whether it causes your cancer to shrink or remain stable. The study will also determine the best length of time over which to inject the study drug through your veins.